

Tue 4th July 2023



Today's issue of *PD*

Pharmacy Daily today features two pages of news, plus a full page from TerryWhite Chemmart.

Extends supply

WELLNEX Life Limited has extended its Supply Agreement with Haleon into the UK, Ireland and the United Arab Emirates, for its soft gel liquid paracetamol.

Director Zack Bozinovski shared that "this Agreement extension highlights the scale benefits of Wellnex's business model of developing innovative products, intellectual property and accelerating distribution via significant partnership arrangements".



Meet finance made for pharmacy



If you are looking for finance, or just want to understand your options, we can provide you with an independent solution.

www.kizmet.capital enquiries@kizmet.capital 1800 054 963

Talk to us today

New NAPSA leadership

THE National Australian Pharmacy Students' Association (NAPSA) has a new leadership team.

Following NAPSA's recent AGM meeting held at RMIT in Melbourne over the weekend, the newly appointed President is Bano Serhan (pictured).

Serhan is in her third year of a Bachelor of Pharmacy (Honours) at the University of Newcastle, NSW.

She will join the NAPSA Board alongside the seven also newly elected Executive Directors who are as follows - Sebastian Harper, Griffith University, Gage Ede and Shylee-Jade Hadar-Pagliari, James Cook University, Harrison Vo, University of Sydney, McKinley Nolan, University of Tasmania, and Ingrid Stroud, University of Canberra.

Serhan acknowledged the work of her predecessor Flynn Swift and shared, "Flynn has offered



incredible knowledge and insight over the past 12 months and I am grateful for his support as I step into the role of the National President"

"It is a privilege to be elected alongside such a highly qualified and dedicated team of Executive Directors.

"I am very excited to work with the Board to continue advancing the excellent work that NAPSA does for our members."

Novartis deal

NOVARTIS will divest 'front of eye' ophthalmology assets to Bausch + Lomb, in a transaction valued up to US\$2.5 billion (A\$3.74 billion), including US\$1.75 billion (A\$2.62 billion) in upfront cash, plus additional milestone payments, with the closing of the deal later this year.

The deal includes Xiidra, the first approved prescription treatment for the signs and symptoms of dry eye disease, and investigational medicine SAF312 (libvatrep), in development as a first-inclass therapy for chronic ocular surface pain, as well as the rights for use of the AcuStream delivery device in dry eye indications and OJL332, a second generation TRPV1 antagonist in pre-clinical development.

RACGP support

THE Royal Australian College of GPs (RACGP) supports the "significant financial boost" for pharmacies, which took effect from 01 Jul (*PD* 03 Jul).

RACGP President Dr Nicole Higgins said, "Australia needs a strong and sustainable primary care system with GPs working together with pharmacists... as community pharmacies play an important role in dispensing medication.

"They also provide various associated services, such as opioid dependence treatment, medication reviews, and Indigenous health, which are government subsidised.

"The significant financial boost to pharmacies from 01 Jul is welcome, particularly for those in our rural communities.

"The regional pharmacy maintenance allowance has doubled, so pharmacies in the most remote areas are now eligible for more than \$90,000 a year to keep their doors open," Higgins said.



DermAid 1%, with dissolved hydrocortisone, has demonstrated up to **4x FASTER ACTIVITY** than dispersed 1% hydrocortisone, as determined by vasoconstriction.¹

Cream

Spray

√ Solution

Achieve a 50% reduction in eczema severity for your patients² with the Ego eczema management action plan.

TREAT
with the
appropriate
topical
corticosteroids

MAINTAIN
with emollier
cleansers
and
moisturisers



Dermâid 1% Hydrocortisone: Topical application for the temporary relief of symptoms associated with acute and chronic corticosteroid responsive conditions including; minor skin irritations, itching and rashes due to eczema, dermatitis, contact dermatitis (such as rashes due to cosmetics and jewellery), psoriasis, anogenital pruritus and sunburn. Dermâid 1% cream: Apply at layer to affected skin 1–2 times daily as required. Dermâid 1% solution: Apply a few drops to the affected area 2-3 times daily as required. Massage in gently. Dermâid 1% spray: Hold bottle approximately 10 cm from the affected skin and apply 1–2 sprays; 2–3 times daily as required. Massage in gently. Dermâid 1 metric proximatications; vaccinic, chicken por, herpes and other viral infections, bacterial infections; buberculosis of the skin and syphilitic skin disorders. Hypersensitivity to hydrocortisone, other corticosteroids or any other ingredient in the product. Do not use in the eye.

Healthcare Professionals: Review the full Product Information (PI) before prescribing or recommending DermAid 1% cream, DermAid 1% solution, DermAid 1% spray. Full PI is available from Ego Pharmaceuticals Pty Ltd and can be accessed at ebs.tga.gov.au

References: 1. Grieve KA, Barnes TM. Increased bioavailability of hydrocortisone dissolved in a cream base. Australas J Dermatol. 2015; 66(2):e30–4. 2. Van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen APM, Arents BWM (2017) Emollients and molstusires of ecerama. Cochrane Database of Systematic Reviews 2017, Issue 2, Art. No.: CD012119. DOI: 10.1009/14651885. C0012119.put/2.

EGO PHARMACEUTICALS PTY LTD

21–31 Malcolm Road, Braeside 3195 Australia australia +61 3 9586 8800 toll free 1800 033 706
"Ego" and "DermAld" are trademarks of Ego Pharmaceuticals Pby Ltd. in Australia and other countries.
©2023 Ego. aski@egopharm.com I www.qrskincare.com.au I Date of Preparation: January 2023.









Tue 4th July 2023





Dispensary Corner

AUSTRALIA'S track record providing healthcare in extreme and remote environments will help space agency NASA's ambitions to reach Mars.

From selecting suitable candidates to helping astronauts transition back to gravity on Earth, Australian researchers and doctors are paving the way for humankind's next foray into space.

"No one in the world does rural healthcare as well as we do, and no one in the world does Antarctic healthcare as well as we do," said Dr John Cherry, a rural medicine specialist and director of the Australasian Society of Aerospace Medicine at Sydney's Kolling Institute.

"Utilising that experience and that knowledge is going to be key to keeping astronauts safe, from a medical point of view, as they venture deeper into space."

The selected candidates will be given medical and technical training to help them deal with everything from medical emergencies to the daily rigours of space on the body.

"Not every astronaut who goes into space is going to be a medical doctor - far from it," said Cherry.

Dr Gordon Cable, a specialist in aerospace medicine whose Adelaide-based startup is developing a post-flight "G-suit" to help astronauts transition back to gravity said, "on Mars, there isn't a welcoming committee, there are no doctors and physios to help you transition - you've got to do it all yourself".

Taking the 'pulse' of pay

THE Pharmacy Guild of Australia is asking for expressions of interest from members of the pharmacy workforce for the 2023/24 financial year Remuneration Survey.

The Guild says its survey will take the "pulse of pay rates" this Aug, and is part of the Pharmacy Guild's Workforce Capability Project.

This survey the Guild feels will help it to "understand factors driving workforce shortages and improvements community pharmacy can make to attract and maintain a skilled workforce".

Pharmacy Guild National President Trent Twomey says the survey is a "great way for the Guild and its members to understand the needs of the workforce".

"By participating you are not only helping your own business to stay competitive but also giving the pharmacy industry an insight into workforce evolution and business sustainability," explained Twomey.

PBS drug listings

ELIGIBILITY criteria for

the COVID-19 oral antiviral

treatment nirmatrelvir and

ritonavir (Paxlovid) will be

to include individuals aged

The change will ensure

greater access to Paxlovid

The PBS eligibly criteria

for molnupiravir (Lagevrio)

Avatrombopag (Doptelet) is

also now listed on the PBS for

thrombocytopenia in patients

the first time to treat severe

thrombocytopenia purpura.

with chronic idiopathic

remains unchanged.

for people who are at risk of

risk factor.

severe disease.

50-59 years with one known

further expanded on the PBS



"The survey is open to both members and non-members alike to participate," he added.

The Guild stated that everyone who participates will also be given an advanced copy of the survey.

The Guild has just published the 2022/23 Remuneration Report after gathering data for this past financial year for participants.

Express your interest in the survey before 16 Jul, HERE.

Dry eye impacts

DEPRESSION can exacerbate the symptoms of chronic dry eye, according to the 'Association Between Depression and Severity of Dry Eye Symptoms, Signs, and Inflammatory Markers in the DREAM Study' published in JAMA Ophthalmology, HERE.

The study found that those who screened positive for depression generally had worse dry eye symptoms.

Depression changes lifestyle habits, such as spending more time in front of a computer or TV, said the study's researchers.

This can lead to dry eyes or worsen your depression.

But it goes both ways, as dry eyes can hurt mental health.



ODT concerns raised with Minister

PHARMACY Guild National President Trent Twomey has expressed concerns over the government's Opioid Dependence Treatment (ODT) policy in a letter to Federal Health Minister Mark Butler.

In the letter, Twomey explains the Guild's concern at the speed of the policy's implementation and that, "ongoing patient access is threatened by impending market failure of the program".

The letter also spells out a lack of consultation and that the policy has a funding shortfall of \$41 million and is funded by, "cuts to pharmacies' dispensing income".

The letter follows seven occasions in which the same concerns were expressed verbally to both the Minister and the Department.

NIP vax addition

THE Vaxelis paediatric hexavalent vaccine is now available on the National Immunisation Program (NIP).

Vaxelis is indicated for primary vaccination in infants from six weeks of age, helping to provide protection against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).



Pharmacy

www.pharmacydaily.com.au

Pharmacy Daily is part of the Business Publishing Group family

Pharmacy Daily is Australia's favourite pharmacy industry publication.

EDITORIAL

Editor in Chief and Publisher – Bruce Piper Associate Publisher - Anna Piper Editor - Jayamala Gupte Contributors - Adam Bishop, Myles Stedman, Janie Medbury,

Sean Harrigan, David Ljucovic & Nicki Harford advertising@pharmacydaily.com.au

ADVERTISING AND MARKETING

BUSINESS MANAGER Jenny Piper

Tel: 1300 799 220 (+61 2 8007 6760) Sign up free at

Suite 1, Level 2, 64 Talavera Rd

Macquarie Park NSW 2113 Australia

PO Box 1010 Epping NSW 1710 Australia

Travel Daily CRUISE Travel & Cruise Weekly trave|Bulletin ˈкᠠ͡ᠵ business events news

www.pharmacydaily.com.au accounts@pharmacydaily.com.au

info@pharmacydaily.com.au

Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.

to grow your pharmacy



60 years of pharmacy and business development experience is behind myTWC.

- Grow your script numbers by making it easier to fulfil scripts exclusively from your pharmacy
- Expand your customer base with online shopping
- Increase average transaction value with scripts, retail sales, rewards, and health services in one app
- Manage your dispensary workflow with flexibility for dispensing scripts and reduced calls as customers can see their digitised scripts

Join Australia's fastest-growing pharmacy network. Call us today.

 Richard Jensch
 (QLD, NT)
 0401 560 712

 Fiona McKenzie
 (ACT, NSW)
 0437 599 920

 Peter O'Brien
 (VIC, TAS)
 0427 352 902

 Jordan Hall
 (WA)
 0419 866 587

 Gary Flynn
 (SA)
 0488 223 155



